Prognostic Parameters in Uveal Melanoma and Their Association with BAP1 Expression

Overview

Journal Br J Ophthalmol

Specialty Ophthalmology

Date 2014 Aug 23

PMID 25147369

Citations 55

Authors

T Huibertus van Essen

Sake I van Pelt

Mieke Versluis

Inge H G Bronkhorst

Sjoerd G van Duinen

Marina Marinkovic

Wilma G M Kroes

Claudia A L Ruivenkamp

Shruti Shukla

Annelies de Klein

Emine Kilic

J William Harbour

Gregorius P M Luyten

Pieter A van der Velden

Rob M Verdijk

Martine J Jager

Affiliations

Soon will be listed here.

Abstract

Aim: To determine whether BAP1 gene and protein expression associates with different prognostic parameters in uveal melanoma and whether BAP1 expression correctly identifies patients as being at risk for metastases, following enucleation of the primary tumour.

Methods: Thirty cases of uveal melanoma obtained by enucleation between 1999 and 2004 were analysed for a variety of prognostic markers, including histological characteristics, chromosome aberrations obtained by fluorescence in situ hybridisation (FISH) and single nucleotide polymorphism (SNP) analysis and gene expression profiling. These parameters were compared with BAP1 gene expression and BAP1 immunostaining.

Results: The presence of monosomy of chromosome 3 as identified by the different chromosome 3 tests showed significantly increased HRs (FISH on isolated nuclei cut-off 30%: HR 11.6, p=0.002; SNP analysis: HR 20.3, p=0.004) for death due to metastasis. The gene expression profile class 2, based on the 15-gene expression profile, similarly provided a significantly increased HR for a poor outcome (HR 8.5, p=0.005). Lower BAP1 gene expression and negative BAP1 immunostaining (50% of 28 tumours were immunonegative) were both associated with these markers for prognostication: FISH cut-off 30% monosomy 3 (BAP1 gene expression: p=0.037; BAP1 immunostaining: p=0.001), SNP-monosomy 3 (BAP1 gene expression: p=0.008; BAP1 immunostaining: p=0.002) and class 2 profile (BAP1 gene expression: p<0.001; BAP1 immunostaining: p=0.001) and were themselves associated with an increased risk of death due to metastasis (BAP1 gene expression dichotomised: HR 8.7, p=0.006; BAP1 immunostaining: HR 4.0, p=0.010).

Conclusions: Loss of BAP1 expression associated well with all of the methods currently used for prognostication and was itself predictive of death due to metastasis in uveal melanoma after enucleation, thereby emphasising the importance of further research on the role of BAP1 in uveal melanoma.

Citing Articles

Identification of diagnostic and prognostic genetic alterations in uveal melanoma using RNA sequencing.

Nell R, Versluis M, Cats D, Mei H, Verdijk R, Kroes W Sci Rep. 2025; 15(1):8167.

PMID: 40059100 PMC: 11891316. DOI: 10.1038/s41598-025-90122-z.

Expanded detection and impact of alterations in cancer.

Sturgill I, Raab J, Hoadley K NAR Cancer. 2024; 6(4):zcae045.

PMID: 39554490 PMC: 11567159. DOI: 10.1093/narcan/zcae045.

Impact of Driver Mutations on Metastasis-Free Survival in Uveal Melanoma: A Meta-Analysis.

Lamas-Francis D, Rodriguez-Fernandez C, de Esteban-Macineira E, Silva-Rodriguez P, Pardo M, Bande-Rodriguez M Cancers (Basel). 2024; 16(14).

PMID: 39061150 PMC: 11274588. DOI: 10.3390/cancers16142510.

complexed with IGF2BP3 drives uveal melanoma progression via regulating N6-methyladenosine modification of .

Zhao A, Wang Y, Wang Z, Shao Q, Gong Q, Zhu H Oncol Res. 2024; 32(5):983-998.

PMID: 38686044 PMC: 11055987. DOI: 10.32604/or.2024.045972.

Mass Spectrometry-Based Profiling of Histone Post-Translational Modifications in Uveal Melanoma Tissues, Human Melanocytes, and Uveal Melanoma Cell Lines - A Pilot Study.

Herwig-Carl M, Sharma A, Tischler V, Pelusi N, Loeffler K, Holz F Invest Ophthalmol Vis Sci. 2024; 65(2):27.

PMID: 38349785 PMC: 10868634. DOI: 10.1167/iovs.65.2.27.

References

Onken M, Worley L, Tuscan M, Harbour J . An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma. J Mol Diagn. 2010; 12(4):461-8. PMC: 2893630. DOI: 10.2353/jmoldx.2010.090220. View

Kivela T, Kujala E . Prognostication in eye cancer: the latest tumor, node, metastasis classification and beyond. Eye (Lond). 2012; 27(2):243-52. PMC: 3574256. DOI: 10.1038/eye.2012.256. View

van Beek J, Koopmans A, Vaarwater J, de Rooi J, Paridaens D, Naus N . The prognostic value of extraocular extension in relation to monosomy 3 and gain of chromosome 8q in uveal melanoma. Invest Ophthalmol Vis Sci. 2014; 55(3):1284-91. DOI: 10.1167/iovs.13-13670. View

van den Bosch T, van Beek J, Vaarwater J, Verdijk R, Naus N, Paridaens D . Higher percentage of FISH-determined monosomy 3 and 8q amplification in uveal melanoma cells relate to poor patient prognosis. Invest Ophthalmol Vis Sci. 2012; 53(6):2668-74. DOI: 10.1167/iovs.11-8697. View

Coupland S, Lake S, Zeschnigk M, Damato B . Molecular pathology of uveal melanoma. Eye (Lond). 2012; 27(2):230-42. PMC: 3574255. DOI: 10.1038/eye.2012.255. View

Kujala E, Damato B, Coupland S, Desjardins L, Bechrakis N, Grange J . Staging of ciliary body and choroidal melanomas based on anatomic extent. J Clin Oncol. 2013; 31(22):2825-31. DOI: 10.1200/JCO.2012.45.2771. View

van Gils W, Lodder E, Mensink H, Kilic E, Naus N, Bruggenwirth H . Gene expression profiling in uveal melanoma: two regions on 3p related to prognosis. Invest Ophthalmol Vis Sci. 2008; 49(10):4254-62. DOI: 10.1167/iovs.08-2033. View

Shah A, Bourne T, Murali R . BAP1 protein loss by immunohistochemistry: a potentially useful tool for prognostic prediction in patients with uveal melanoma. Pathology. 2013; 45(7):651-6. DOI: 10.1097/PAT.0000000000000002. View

Harbour J . Molecular prognostic testing and individualized patient care in uveal melanoma. Am J Ophthalmol. 2009; 148(6):823-9.e1. PMC: 4470132. DOI: 10.1016/j.ajo.2009.07.004. View

10.

Du P, Kibbe W, Lin S . lumi: a pipeline for processing Illumina microarray. Bioinformatics. 2008; 24(13):1547-8. DOI: 10.1093/bioinformatics/btn224. View

11.

Scheuermann J, de Ayala Alonso A, Oktaba K, Ly-Hartig N, McGinty R, Fraterman S . Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB. Nature. 2010; 465(7295):243-7. PMC: 3182123. DOI: 10.1038/nature08966. View

12.

Lin S, Du P, Huber W, Kibbe W . Model-based variance-stabilizing transformation for Illumina microarray data. Nucleic Acids Res. 2008; 36(2):e11. PMC: 2241869. DOI: 10.1093/nar/gkm1075. View

13.

Laurent C, Gentien D, Piperno-Neumann S, Nemati F, Nicolas A, Tesson B . Patient-derived xenografts recapitulate molecular features of human uveal melanomas. Mol Oncol. 2013; 7(3):625-36. PMC: 4966164. DOI: 10.1016/j.molonc.2013.02.004. View

14.

Worley L, Onken M, Person E, Robirds D, Branson J, Char D . Transcriptomic versus chromosomal prognostic markers and clinical outcome in uveal melanoma. Clin Cancer Res. 2007; 13(5):1466-71. DOI: 10.1158/1078-0432.CCR-06-2401. View

15.

Scholes A, Damato B, Nunn J, Hiscott P, Grierson I, Field J . Monosomy 3 in uveal melanoma: correlation with clinical and histologic predictors of survival. Invest Ophthalmol Vis Sci. 2003; 44(3):1008-11. DOI: 10.1167/iovs.02-0159. View

16.

White V, Chambers J, Courtright P, Chang W, Horsman D . Correlation of cytogenetic abnormalities with the outcome of patients with uveal melanoma. Cancer. 1998; 83(2):354-9. View

17.

Onken M, Lin A, Worley L, Folberg R, Harbour J . Association between microarray gene expression signature and extravascular matrix patterns in primary uveal melanomas. Am J Ophthalmol. 2005; 140(4):748-9. DOI: 10.1016/j.ajo.2005.04.024. View

18.

Bronkhorst I, Maat W, Jordanova E, Kroes W, Schalij-Delfos N, Luyten G . Effect of heterogeneous distribution of monosomy 3 on prognosis in uveal melanoma. Arch Pathol Lab Med. 2011; 135(8):1042-7. DOI: 10.5858/2010-0477-OAR1. View

19.

Tschentscher F, Husing J, Holter T, Kruse E, Dresen I, Jockel K . Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities. Cancer Res. 2003; 63(10):2578-84. View

20.

Damato B, Coupland S . Translating uveal melanoma cytogenetics into clinical care. Arch Ophthalmol. 2009; 127(4):423-9. DOI: 10.1001/archophthalmol.2009.40. View